Biogen Inc. (BIIB) Stock Price & Analysis
Biogen Inc. (BIIB) rose 3.36% to USD 199.1 as of June 9, 2026 at 22:40 UTC, according to Nexqual real-time market data.
BIIB last closed at USD 192.62; the session ranged USD 193.48–199.63 on volume of 922,061 shares. Market capitalization is $29.39B, with a 52-week range of USD 121.05–205.97 (NMS). Source: Nexqual, June 9, 2026 at 22:40 UTC.
Key Statistics (as of June 9, 2026 at 22:40 UTC)
| Price | USD 199.1 |
|---|---|
| Change | ▲ 3.36% (up) |
| Previous Close | USD 192.62 |
| Open | USD 195.51 |
| Day Range | USD 193.48 – 199.63 |
| 52-Week Range | USD 121.05 – 205.97 |
| Volume | 922,061 shares |
| Market Cap | $29.39B |
| Exchange | NMS |
Technical Analysis (BIIB)
Nexqual's technical model rates BIIB "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 22:40 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.01 (neutral) |
| vs SMA50 | Above (USD 188) |
| MACD | 1.81 (positive) |
Analyst Ratings (BIIB)
Wall Street analysts rate BIIB "Buy" based on 29 analysts, with a mean price target of USD 219.44 (range USD 150–300), per Nexqual as of June 9, 2026 at 22:40 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 219.44 |
| High Target | USD 300 |
| Low Target | USD 150 |
| Buy / Hold / Sell | 20 / 15 / 1 |
Earnings (BIIB)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.94 |
| Revenue Estimate | $2.42B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 3.57 vs est 2.89 ▲ beat |
| 2025-12-31 | USD 1.99 vs est 1.62 ▲ beat |
| 2025-09-30 | USD 4.81 vs est 3.88 ▲ beat |
| 2025-06-30 | USD 5.47 vs est 3.88 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Financials & Fundamentals (BIIB)
| Total Revenue | $9.94B |
|---|---|
| Revenue Growth (YoY) | +1.90% |
| Gross Margin | +78.72% |
| Operating Margin | +22.90% |
| Profit Margin | +13.80% |
| ROE | +7.70% |
| Debt / Equity | 35.18 |
| Current Ratio | 3.07 |
| Total Cash | $4.28B |
| Total Debt | $6.56B |
| Free Cash Flow | $1.93B |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Financial Health Score (BIIB)
Nexqual rates Biogen Inc.'s overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:40 UTC.
| Growth | Mixed — Revenue +2.2% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 79%, operating 23% |
| Balance Sheet | Strong — $4.28B cash vs $6.56B debt |
| Cash Flow | Strong — FCF $1.93B, 20% margin |
| Efficiency | Mixed — ROE 8%, ROA 6.0% |
Ownership (BIIB)
| Insider Ownership | +0.17% |
|---|---|
| Institutional Ownership | +96.59% |
| Shares Outstanding | 147.64M |
| Float | 147.20M |
| Short % of Float | +3.57% |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Leadership (BIIB)
Biogen Inc. is led by Christopher A. Viehbacher (age 64), President, CEO & Director, per Nexqual as of June 9, 2026 at 22:40 UTC.
| President, CEO & Director | Christopher A. Viehbacher (age 64) |
|---|---|
| Executive VP & CFO | Robin C. Kramer (age 59) |
| President & Head of North America | Alisha A. Alaimo |
Major Backers & Investors (BIIB)
Notable institutional backers of Biogen Inc. include Primecap Management Company, FMR, LLC, Fidelity, according to Nexqual as of June 9, 2026 at 22:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Primecap Management Company | 10% |
| FMR, LLC | 8.68% |
| Fidelity | 3.94% |
| Wellington Management | 2.01% |
| Morgan Stanley | 1.47% |
| JPMorgan | 1.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 27.92% |
| BlackRock | 12.11% |
| State Street | 6.05% |
| Geode Capital | 2.94% |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
From Biogen Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
- The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | USD 616.18 | ▼ 3.03% |
| AMGN | Amgen Inc. | USD 344.57 | ▼ 1.43% |
| GILD | Gilead Sciences, Inc. | USD 125.5 | ▼ 2.83% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 445.77 | ▼ 0.24% |
| ILMN | Illumina, Inc. | USD 160.03 | ▼ 1.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:40 UTC. This page is informational and not investment advice.